[{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","commit":"1fcb3c8eab","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on the remaining institutions and thirty more companies","file":"src/data/spikes/rcc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.eisai.com\" }]"}]},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","commit":"afc6af185b","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: ovarian, endometrial, cervical cancer deep dives (74 new entities with structured outcomes, dosing, toxicity, regulatory events, gui","file":"src/data/spikes/endometrial.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","commit":"06611b41fb","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: SCLC, mesothelioma, urothelial, RCC deep dives with structured outcomes, dosing, toxicity, regulatory events","file":"src/data/spikes/rcc.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"asOf"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","commit":"06899fbdf4","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: hepatocellular carcinoma, biliary tract cancer, neuroendocrine tumours (deep, with structured outcomes, dosing, toxicity, regulatory","file":"src/data/spikes/hcc.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]}]